Prot #SMX 18-001: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutat

  • Shah, Ami N (PD/PI)

Project: Research project

Project Details

StatusActive
Effective start/end date5/28/20 → 5/28/26

Funding

  • Linical Americas ((OE) Prot #SMX 18-001 // (OE) Prot #SMX 18-001)
  • Sermonix Pharmaceuticals, Inc. ((OE) Prot #SMX 18-001 // (OE) Prot #SMX 18-001)